We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+17.27%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.99B
AUM Growth
+$232M
(+13%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
3.27%
Top 10 Holdings %
Top 10 Hldgs %
47.8%
Holding
194
New
23
Increased
33
Reduced
38
Closed
65
Avg Time Held Equity + Options
4.7
quarters
Top 10 Avg Time Held Equity + Options
5.1
quarters
Top 20 Avg Time Held Equity + Options
6.3
quarters
Avg Time Held Equity only
4.9
quarters
Top 10 Avg Time Held Equity only
5.1
quarters
Top 20 Avg Time Held Equity only
6.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$46.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$41M |
| 3 |
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
|
+$35.9M |
| 4 |
CORI
Corium International, Inc.
CORI
|
+$19M |
| 5 |
Intuitive Surgical
ISRG
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$37.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$22.2M |
| 3 |
NEVRO CORP.
NVRO
|
+$20.4M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$13.3M |
| 5 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$12.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.26% |
| 2 | Miscellaneous | 3.45% |
| 3 | Consumer Staples | 0.19% |
| 4 | Consumer Discretionary | 0.06% |
| 5 | Energy | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Amicus Therapeutics
FOLD
| $174M | 8.76% |
17,296,672
| – | – |
2014 Q1
13 quarters
|
|
2
Neurocrine Biosciences
NBIX
$14.4B
| $165M | 8.28% |
3,577,589
+211,059
| +6% | +$10.2M |
2013 Q2
16 quarters
|
|
|
3
Alnylam Pharmaceuticals
ALNY
$30.4B
| $146M | 7.36% |
1,832,761
+729,286
| +66% | +$46.6M |
2016 Q4
2 quarters
|
|
|
GBT
4
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $108M | 5.41% |
3,933,927
+74,949
| +2% | +$2.23M |
2015 Q3
7 quarters
|
|
|
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
| $76.9M | 3.87% |
734,553
| – | – |
2014 Q1
13 quarters
|
|
|
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $64.2M | 3.23% |
2,157,011
+17,737
| +0.8% | +$508K |
2014 Q3
11 quarters
|
|
|
7
Puma Biotechnology
PBYI
$531M
| $64.1M | 3.23% |
+733,320
| New | +$41M |
2017 Q2
0 quarters
|
|
8
Travere Therapeutics
TVTX
$4.9B
| $51.8M | 2.61% |
2,672,309
-135,216
| -5% | -$2.45M |
2014 Q1
13 quarters
|
|
|
TSRO
9
DELISTED
TESARO, Inc.
TSRO
| $50.3M | 2.53% |
359,551
+118,523
| +49% | +$17.2M |
2013 Q2
16 quarters
|
|
|
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
| $50M | 2.52% |
3,448,302
+1,245,000
| +57% | +$15.6M |
2016 Q3
3 quarters
|
|
|
CORI
11
DELISTED
Corium International, Inc.
CORI
| $43.6M | 2.2% |
5,847,133
+3,192,648
| +120% | +$19M |
2017 Q1
1 quarter
|
|
|
NXTM
12
DELISTED
NxStage Medical Inc.
NXTM
| $39M | 1.96% |
1,555,523
-262,666
| -14% | -$6.5M |
2016 Q2
4 quarters
|
|
|
DOVA
13
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $38M | 1.91% |
+1,706,499
| New | +$35.9M |
2017 Q2
0 quarters
|
|
|
14
Sarepta Therapeutics
SRPT
$1.84B
| $36.7M | 1.85% |
1,089,961
-681,068
| -38% | -$22.2M |
2013 Q2
16 quarters
|
|
15
Vertex Pharmaceuticals
VRTX
$129B
| $35.7M | 1.8% |
277,352
-16,157
| -6% | -$1.94M |
2015 Q4
6 quarters
|
|
16
Iovance Biotherapeutics
IOVA
$6.6B
| $32.1M | 1.61% |
4,363,114
+795,561
| +22% | +$5.06M |
2015 Q1
9 quarters
|
|
17
DELISTED
Radius Health, Inc.
RDUS
| $29.2M | 1.47% |
645,873
-264,999
| -29% | -$10.1M |
2016 Q3
3 quarters
|
|
18
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $28.6M | 1.44% |
218,861
| – | – |
2015 Q1
9 quarters
|
|
19
Xencor
XNCR
$1.86B
| $27.3M | 1.37% |
1,293,095
-313,923
| -20% | -$7.04M |
2013 Q4
14 quarters
|
|
20
Evolent Health
EVH
$481M
| $27.2M | 1.37% |
1,074,327
-370,173
| -26% | -$8.9M |
2015 Q2
8 quarters
|
|
21
Regenxbio
RGNX
$513M
| $27.1M | 1.36% |
1,371,186
-25,058
| -2% | -$485K |
2015 Q3
7 quarters
|
|
|
QTNT
22
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $26M | 1.31% |
92,862
+19,917
| +27% | +$5.62M |
2014 Q2
12 quarters
|
|
23
AnaptysBio
ANAB
$1.38B
| $22.8M | 1.15% |
952,269
+70,312
| +8% | +$1.77M |
2017 Q1
1 quarter
|
|
24
DELISTED
Blueprint Medicines
BPMC
| $22.5M | 1.13% |
444,661
-16,981
| -4% | -$721K |
2015 Q2
8 quarters
|
|
|
AVXS
25
DELISTED
AveXis, Inc. Common Stock
AVXS
| $22.3M | 1.12% |
271,181
-177,320
| -40% | -$13.3M |
2016 Q1
5 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2017 Portfolio in Review
As of Q2 2017, Perceptive Advisors held 194 positions worth $1.99B, up 13% from $1.76B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors deployed $64.9M of net new capital in Q2 2017, opening 23 new positions and adding to 33 existing holdings. Its largest new stake was Puma Biotechnology: 733,320 shares worth $64.1M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $22.2M trimmed.
- Perceptive Advisors's largest Q2 2017 buy was Puma Biotechnology: 733,320 shares worth $64.1M.
- Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2017, an estimated $46.6M increase.
- Perceptive Advisors's biggest Q2 2017 reduction was Sarepta Therapeutics, cutting an estimated $22.2M.
- Perceptive Advisors fully exited Aclaris Therapeutics in Q2 2017, selling an estimated $37.6M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.99B portfolio in Q2 2017.
- Perceptive Advisors opened 23 new positions and closed 65 in Q2 2017.
- Perceptive Advisors's portfolio value rose 13% quarter-over-quarter to $1.99B.
Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.